ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000.

This should not be seen as good news for any given technology (iFR, in this case), but for physiologic assessment as a general concept. Many more interventional cardiologists need to start using physiologic assessment as a standard course of action in their cath labs, because there is much evidence that it improves outcomes.

 

FFR requires maximum hyperemia, which is achieved by using adenosine—with its associated side effects and costs. On the other hand, iFR calculates the pressure gradient of a lesion during diastole, immediately after the dicrotic wave, when physiologic resistance is minimum. That renders unnecessary the use of hyperemic agents.


Read also: NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising.


Last year, DEFINE-FLAIR and iFR-SWEDEHEART results proved the noninferiority of iFR in terms of events compared with FFR measurement.

 

The difference in terms of costs is driven by the fact that FFR-guided procedures identified more significant lesions that required treatment. More time must go by for the assessment of this aspect. If, in the future, some lesions left untreated with iFR require reintervention, the equation might be inverted by the late catch-up phenomenon. The opposite might also turn out to be true: less stenting with iFR might derive in less restenosis and less future thrombosis.

 

Original title: Comparative Cost-Effectiveness of the Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Coronary Revascularization Decision-Making.

Presenter: Patel MR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...